知镜 Cognispect · 医学文献与研究工作台

Detection of androgen receptor (AR) splice variants across diverse prostatic and non-prostatic tumor types using the TruSight Oncology 500 (TSO500) assay.

Pitel BA, Dasari S, Pryzbylski AL, Childs DS, Poljak D, Keeney M, Geiersbach K, Lucas PC, Orme JJ, Heath EI, Whaley RD, Garcia JJ, Erickson LA, Cheville JC, Shen W, Zheng G, Al-Kateb H, Kipp BR, Halling KC, Antonarakis ES, Gupta S.
Human pathology · 2026-09-11 · PMID 42727615

文献摘要

Background Androgen Receptor splice variants (AR-Vs) are known biomarkers of resistance to hormone therapy in prostate (CaP) and breast cancer (BC). However, pancancer interrogations of AR-Vs are lacking. Methods The MayoComplete Solid Tumor Panel, with DNA and RNA subpanels targeting 515 and 55 genes, respectively, was used to profile 5573 solid tumors. Relevant clinicopathologic and molecular features were summarized for tumors with detectable AR-Vs. Results AR-Vs were identified in 46 of 5573 (0.8%) tumors from 28 males and 18 females with a mean age of 68 years (range, 11 to 98). AR-Vs were enriched in CaP (24/132, 18.2%), BC (17/208, 8.2%), and salivary duct carcinomas (2/38, 5.3%), with rare occurrences in a lacrimal gland carcinoma and juvenile granulosa cell tumor. While AR-V7 was observed in all 46 tumors (100%), AR-V7 in the absence of other AR-Vs was seen in only 2 (of 46, 4.3%) tumors. Associated AR alterations in CaP included AR amplification (n = 3) and AR ligand binding domain (LBD) mutations (n = 2), while associated ESR1 variants in BC included ESR1 LBD mutations (n = 2) and ESR1 rearrangements (n = 2). Of patients with accessible medical records, 2/8 (25%) CaP patients had AR-Vs post-therapy with AR signaling inhibitors. Similarly, 5/6 (83.3%) BC patients had AR-Vs post-hormonal therapy. Notably, all 14 patients had multiple AR-V species. Conclusions Our results demonstrate enrichment of AR-Vs in prostate, breast, and salivary duct carcinomas, with rare occurrences in a lacrimal gland carcinoma and juvenile granulosa cell tumor. Multiple AR-Vs were frequently seen in the same tumor. Detection of AR-Vs may be clinically significant in prostate cancer and additional data is needed for other tumor types.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。